NEW YORK (GenomeWeb News) – Applied Proteomics and The ALS Therapy Development Institute (ALS TDI) are collaborating to validate protein biomarkers for tracking the progression of, and developing therapies for, amyotrophic lateral sclerosis, also called Lou Gehrig's disease.

"The absence of viable diagnostic and therapeutic tools for managing and treating ALS is tragic," John Blume, CSO at Applied Proteomics, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.